News

Have you ever wondered what the letters and numbers stamped on the surface of a pill mean?

Amgen licenses AMG 634, an investigational treatment for tuberculosis and leprosy, to medicines development for global health...

The Mectizan (ivermectin) Expert Committee states that new in vitro data are not sufficient to indicate clinical benefit to reduce viral loads in COVID-19 patients...

January 30, 2020 marks the first ever World Neglected Tropical Disease Day. It is billed as 'A New Day in the Fight Against NTDs' and kicks off a decisive year in the fight against NTDs...

Mark Sullivan, Managing Director and Founder of Medicines for Global Health, was awarded one of EY Australia's "Entrepreneur of the Year" awards in the social category for his work in establishing MDGH...

Significant portion of proceeds will be reinvested in neglected disease research and control efforts, fully realizing the original intent of this important public health funding mechanism‍...

Awarded annually, the Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments...

The award is for his vision in establishing Medicines Development for Global Health to address health inequity, and the novel funding approach that was applied...

The sale of the Tropical Disease Priority Review Voucher follows the FDA’s approval of moxidectin, an oral treatment for river blindness...

Fast Company is a highly-regarded magazine based in New York. It is dedicated to the intersection of business, innovation, and design, and engages with the world’s most influential leaders and companies on the future of business...

Medicines Development for Global Health (MDGH) is delighted to announce that it has received the 2018 AusBiotech and Johnson & Johnson Innovation Industry Excellence Award in the “Established Company of the Year Award” category.

Medicines Development for Global Health Founder and Managing Director Mark Sullivan was named 2019 Victorian Australian of the Year this week for his vision for bringing urgently needed medicines into the fight against Neglected Tropical Diseases.‍

Mark Sullivan, the founder, Managing Director and Board Member of Medicines Development for Global Health, was interviewed by Dr. Norman Swan on today’s Health Report, broadcast nationally in Australia. The interview covers MDGH’s business model, the FDA’s approval of Moxidectin, and the medicine’s potential to help the fight against river blindness, which is a leading global cause of preventable blindness. Click anywhere to listen to a recording on the ABC’s website.

Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The FDA has also awarded MDGH a priority review voucher ....

The Rotavirus Vaccine Program at the Murdoch Children’s Research Institute has published results from their study evaluating the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing rotavirus gastroenteritis. Amanda Handley, Director at Medicines Development, has been providing project management services on this program since January 2013. Congratulations to all the program team...

Medicines Development for Global Health is delighted to announce the publication of the moxidectin Phase III study in the Lancet. The paper’s authors, coordinated by the previous Sponsor of moxidectin, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, concluded that “Moxidectin would therefore be expected to reduce parasite transmission between treatment...

The February 2018 edition of Clinical Researcher’s Q & A with Mark Sullivan and Craig Rayner on good management practice. Please click here to read the Q&A.

Medicines Development for Global Health is pleased to announce the submission of a New Drug Application for moxidectin as an oral treatment for river blindness to the US Food and Drug Administration (FDA). The FDA have also confirmed that moxidectin has qualified for priority review.

Medicines Development is pleased to announce that it has been accepted as a member of the Neglected Tropical Disease NGO Network (NNN), a global forum for nongovernmental organizations working together on NTDs. The NNN was established in October 2009 to create a global forum for nongovernmental organizations working to control onchocerciasis, lymphatic filariasis, schistosomiasis, soil transmitted helminths and trachoma. There is a long list of esteemed members in this network.

There are two bills on FDA reauthorization in the US Congress aimed at improving the FDA Priority Review Program for Neglected Tropical Diseases. The neglected tropical diseases world is benefiting from this prescient legislation to address the market failure in neglected tropical diseases. However, in reviewing the proposed legislation, there are some unexpected and potentially undesirable consequences to the proposed changes.